drugset / Trial / NCT01479231

Predictors of Proton Pump Inhibitor (PPI) Response in Eosinophilic Esophagitis

NCT01479231

Phase 1/2 Withdrawn Mayo Clinic
NaSingle-groupOpen-labelTreatment

Summary

The investigators will determine the prevalence of gastroesophageal reflux disease (GERD) in Eosinophilic Esophagitis (EoE) and importantly determine the predictors of response to Proton Pump Inhibitor (PPI) therapy in EoE. Moreover, the investigators will determine the effect of GERD on the location of esophageal eosinophilia.

Timeline

Start
2012-03
Primary completion
2012-03
Completion
2012-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Dexlansoprazole Other / unclassified 60 mg